SG11201402312WA - Anticancer fusion protein - Google Patents

Anticancer fusion protein

Info

Publication number
SG11201402312WA
SG11201402312WA SG11201402312WA SG11201402312WA SG11201402312WA SG 11201402312W A SG11201402312W A SG 11201402312WA SG 11201402312W A SG11201402312W A SG 11201402312WA SG 11201402312W A SG11201402312W A SG 11201402312WA SG 11201402312W A SG11201402312W A SG 11201402312WA
Authority
SG
Singapore
Prior art keywords
fusion protein
anticancer fusion
anticancer
protein
fusion
Prior art date
Application number
SG11201402312WA
Other languages
English (en)
Inventor
Jerzy Szczepan Pieczykolan
Sebastian Pawlak
Michal Szymanik
Anna Maria Pieczykolan
Bartlomiej Maciej Zerek
Piotr Rózga
Albert Robert Jaworski
Malgorzata Izabela Teska-Kaminska
Original Assignee
Adamed Sp Zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Sp Zoo filed Critical Adamed Sp Zoo
Publication of SG11201402312WA publication Critical patent/SG11201402312WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201402312WA 2011-11-28 2012-11-28 Anticancer fusion protein SG11201402312WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL397167A PL397167A1 (pl) 2011-11-28 2011-11-28 Przeciwnowotworowe bialko fuzyjne
PCT/IB2012/056806 WO2013080147A2 (en) 2011-11-28 2012-11-28 Anticancer fusion protein

Publications (1)

Publication Number Publication Date
SG11201402312WA true SG11201402312WA (en) 2014-06-27

Family

ID=47561689

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201402312WA SG11201402312WA (en) 2011-11-28 2012-11-28 Anticancer fusion protein

Country Status (18)

Country Link
US (1) US20150044162A1 (enrdf_load_stackoverflow)
EP (1) EP2785362A2 (enrdf_load_stackoverflow)
JP (1) JP2015500228A (enrdf_load_stackoverflow)
KR (1) KR20140097529A (enrdf_load_stackoverflow)
CN (1) CN103974711A (enrdf_load_stackoverflow)
AU (1) AU2012345494A1 (enrdf_load_stackoverflow)
BR (1) BR112014012808A2 (enrdf_load_stackoverflow)
CA (1) CA2856480A1 (enrdf_load_stackoverflow)
EA (1) EA201491049A1 (enrdf_load_stackoverflow)
HK (1) HK1201727A1 (enrdf_load_stackoverflow)
IL (1) IL232743A0 (enrdf_load_stackoverflow)
IN (1) IN2014CN04498A (enrdf_load_stackoverflow)
MX (1) MX2014006369A (enrdf_load_stackoverflow)
PH (1) PH12014501083A1 (enrdf_load_stackoverflow)
PL (1) PL397167A1 (enrdf_load_stackoverflow)
SG (1) SG11201402312WA (enrdf_load_stackoverflow)
WO (1) WO2013080147A2 (enrdf_load_stackoverflow)
ZA (1) ZA201404667B (enrdf_load_stackoverflow)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2800630T3 (es) 2013-03-12 2021-01-04 Molecular Templates Inc Proteínas citotóxicas que comprenden regiones de unión de reconocimiento celular y regiones de la subunidad A de la toxina Shiga para la eliminación selectiva de tipos de células específicas
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
US20160347798A1 (en) 2014-01-27 2016-12-01 Molecular Templates, Inc. Mhc class i epitope delivering polypeptides and cell-targeted molecules for direct cell killing and immune stimulation via mhc class i presentation and methods regarding the same
US20170002046A1 (en) * 2014-03-11 2017-01-05 Molecular Templates, Inc. Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
ES2717751T3 (es) * 2014-06-11 2019-06-25 Molecular Templates Inc Polipéptidos efectores de la subunidad A de la toxina de Shiga resistentes a la escisión por proteasa y moléculas dirigidas a células que los comprenden
JP6444486B2 (ja) 2015-02-05 2018-12-26 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 志賀毒素ａサブユニットエフェクター領域を含む多価ｃｄ２０結合分子及びそれらの強化組成物
WO2016127346A1 (zh) * 2015-02-11 2016-08-18 四川大学华西医院 一种肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
HRP20200640T1 (hr) * 2015-05-30 2020-07-10 Molecular Templates, Inc. De-imunizirane, okosnice podjedinice shiga toksina a i molekule koje ciljaju stanice koje ih sadrže
CN106380521B (zh) 2015-07-02 2020-12-29 博际生物医药科技(杭州)有限公司 用于肿瘤靶向治疗的白细胞介素-15融合蛋白
KR101732126B1 (ko) 2015-11-05 2017-05-02 한국생명공학연구원 췌장암 치료용 융합 단백질 및 이의 용도
PL233352B1 (pl) * 2016-09-15 2019-10-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe białko fuzyjne
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
CN106632680A (zh) * 2016-12-27 2017-05-10 上海交通大学 植物体系表达人源化抗agr2单克隆抗体18a4的质粒构建
JP7082424B2 (ja) 2017-01-25 2022-06-08 モレキュラー テンプレーツ，インク． 脱免疫化された志賀毒素ａサブユニットエフェクター及びｃｄ８＋ｔ細胞エピトープを含む細胞標的化分子
JP2021515774A (ja) * 2018-03-06 2021-06-24 ザ・ジョンズ・ホプキンス・ユニバーシティ 制御性ｔ細胞を枯渇する薬剤、及びチェックポイント阻害剤を使用してがんを治療、又は予防する方法
AU2019257343A1 (en) 2018-04-17 2020-09-10 Molecular Templates, Inc. HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds
WO2020234498A2 (es) * 2019-05-15 2020-11-26 Universidad De Granada Terapia génica con los genes hokd y ldrb para el tratamiento del cáncer
CN113354738B (zh) * 2020-03-05 2022-09-09 绍兴德方华生物技术有限公司 融合毒素VEGF165b/mGEL及其编码基因与应用
JP2023538563A (ja) * 2020-08-17 2023-09-08 エーティービー セラピューティクス リボトキシンまたはＲＮＡｓｅを含む組換え免疫毒素
CN114681599B (zh) * 2020-12-31 2024-07-02 中国科学院上海药物研究所 一种阳离子脂质体疫苗及其制备方法和用途
CN117384859B (zh) * 2023-12-13 2024-03-22 北京翊博生物集团有限公司 一种树突状细胞来源的外泌体的制备方法及应用
CN118792375B (zh) * 2024-06-25 2025-09-23 华南农业大学 一种具有补肾壮阳功效的瓜蒌多肽及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE503013T1 (de) 1995-06-29 2011-04-15 Immunex Corp Cytokin welches apoptose induziert
WO2001060393A1 (en) 2000-02-16 2001-08-23 Bechtel Bwxt Idaho, Llc Selective destruction of cells infected with human immunodeficiency virus
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
CN1257187C (zh) * 2003-10-22 2006-05-24 上海恰尔生物技术有限公司 钙网蛋白－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
ATE501256T1 (de) 2003-11-03 2011-03-15 Beijing Sunbio Biotech Co Ltd Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung
US7252993B2 (en) 2004-03-12 2007-08-07 Battelle Energy Alliance, Llc Plasmids encoding therapeutic agents
EP3006457B1 (en) 2005-07-29 2017-11-22 The Government of the United States of America, as represented by the Secretary of Health and Human Services Mutated pseudomonas exotoxins with reduced antigenicity
EP2287615A1 (en) 2005-08-16 2011-02-23 Genentech, Inc. Apoptosis sensitivity to APO2L/TRAIL by testing for GALNAC-T14 expression in cells/tissues
CA2668017A1 (en) 2006-10-30 2008-05-08 Viventia Biotech Inc. Improved conjugates
SG163558A1 (en) 2006-12-29 2010-08-30 Osprey Pharmaceuticals Usa Inc Methods of selecting and producing modified toxins, conjugates containing modified toxins and uses thereof
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
KR101749310B1 (ko) * 2008-01-24 2017-06-21 에스퍼란스 파마슈티컬스, 인코포레이티드 용해 도메인 융합 구성물 및 이를 제조하고 사용하는 방법
WO2009140469A2 (en) 2008-05-14 2009-11-19 Genentech, Inc. Methods of using apo2l/trail to treat cancer
CN102137869B (zh) * 2008-06-30 2018-07-06 宾夕法尼亚大学 Fn14/TRAIL融合蛋白

Also Published As

Publication number Publication date
IN2014CN04498A (enrdf_load_stackoverflow) 2015-09-11
PH12014501083A1 (en) 2014-08-04
EP2785362A2 (en) 2014-10-08
EA201491049A1 (ru) 2014-10-30
MX2014006369A (es) 2014-07-09
US20150044162A1 (en) 2015-02-12
WO2013080147A3 (en) 2014-02-13
WO2013080147A2 (en) 2013-06-06
JP2015500228A (ja) 2015-01-05
IL232743A0 (en) 2014-07-31
PL397167A1 (pl) 2013-06-10
ZA201404667B (en) 2015-09-30
CA2856480A1 (en) 2013-06-06
HK1201727A1 (en) 2015-09-11
BR112014012808A2 (pt) 2019-09-24
CN103974711A (zh) 2014-08-06
KR20140097529A (ko) 2014-08-06
AU2012345494A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
ZA201404667B (en) Anticancer fusion protein
ZA201300677B (en) Anticancer fusion protein
PL2551190T3 (pl) Zmiennopłat
SI2661496T1 (sl) Fuzijski protein proti raku
ZA201405460B (en) Anticancer fusion protein
ZA201303449B (en) Anticancer fusion protein
EP2698386B8 (en) Fusion protein
ZA201308597B (en) Anticancer fusion protein
EP2657337A4 (en) FUSION PROTEIN
ZA201207425B (en) Fusion protein
GB201213672D0 (en) Protein
PL393146A1 (pl) Przeciwnowotworowe białko fuzyjne
HK1189602A (en) Anticancer fusion protein
GB201114701D0 (en) Fusion proteins
GB201107189D0 (en) Fusion proteins
AU4710P (en) Fusion xTriticosecale
GB201104152D0 (en) Fusion Polypeptide
HUP1100282A2 (en) Protein factor
AU2011905145A0 (en) Fusion Protein
GB201204065D0 (en) Fusion polypeptide
GB201112985D0 (en) Polypeptide
GB201112849D0 (en) Polypeptide
GB201106130D0 (en) Polypeptide
GB201103169D0 (en) Protein expression